Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 6/20 | 0.35 |
| ▸ | CA12 | O43570 | 4/20 | 0.33 |
| ▸ | CA1 | P00915 | 4/20 | 0.33 |
| ▸ | CA4 | P22748 | 4/20 | 0.33 |
| ▸ | CA9 | Q16790 | 4/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.30 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
| ▸ | TLR2 | O60603 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20777434 | 0.88 | EPHX2 (0.38) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL24591872 | 0.85 | CA2 (0.39) | MEN1KMT2ASMN1; SMN2CA2CA12 | |
| SCHEMBL16329782 | 0.84 | — | — | |
| SCHEMBL25779298 | 0.84 | MEN1 (0.38) | MEN1KMT2ASMN1; SMN2CA2CA12 | |
| SCHEMBL14147993 | 0.84 | MEN1 (0.45) | MEN1KMT2ASMN1; SMN2CA2CA12 | |
| SCHEMBL22214463 | 0.83 | MEN1 (0.44) | MEN1KMT2ASMN1; SMN2CA2CA12 | |
| SCHEMBL20822013 | 0.81 | MEN1 (0.44) | MEN1KMT2ASMN1; SMN2CA2CA12 | |
| SCHEMBL16303451 | 0.81 | MEN1 (0.41) | MEN1KMT2ASMN1; SMN2CA2CA12 | |
| SCHEMBL16416580 | 0.81 | SMN1; SMN2 (0.42) | MEN1KMT2ASMN1; SMN2CA2CA12 | |
| SCHEMBL14074912 | 0.81 | MEN1 (0.41) | MEN1KMT2ASMN1; SMN2CA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212103-A1 | POLYETHYLENE GLYCOL DERIVATIVE AND USE THEREOF | HANMI PHARM. CO., LTD. (KR) | 2023-07-06 | — | — | US | disclosed |
| US-20230212103-A1 | POLYETHYLENE GLYCOL DERIVATIVE AND USE THEREOF | HANMI PHARM. CO., LTD. (KR) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212103-A1 | POLYETHYLENE GLYCOL DERIVATIVE AND USE THEREOF | RPN2, MPDU1, RPN1 | MEN1 2947/4885KMT2A 4395/4885SMN1; SMN2 2864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.